Splenectomy for hereditary spherocytosis: complete, partial or not at all?

Area of Science:

• Hematology
• Genetics
• Pediatrics

Background:

• Hereditary spherocytosis (HS) is a common Northern European hemolytic anemia.
• It stems from intrinsic erythrocyte membrane defects leading to spleen destruction of red blood cells.
• Splenomegaly and hemolytic anemia are key clinical features.

Purpose of the Study:

• To critically review and address controversies in hereditary spherocytosis management.
• To highlight the risks and benefits of splenectomy, especially in pediatric HS.
• To discuss the lack of strong evidence in certain HS management aspects.

Main Methods:

• Literature review and critical analysis of existing data on HS management.
• Discussion of controversial aspects of HS treatment based on author's viewpoint.
• Examination of the risks and benefits of splenectomy in pediatric patients.

Main Results:

• Splenectomy effectively resolves anemia and hyperbilirubinemia in HS by removing the spleen's destructive role.
• However, splenectomy carries significant risks, particularly in children.
• Current evidence is insufficient for definitive guidelines on HS management, leading to potential clinical controversies.

Conclusions:

• Splenectomy is a viable therapeutic option for hereditary spherocytosis but requires careful consideration of risks versus benefits.
• Erroneous splenectomy recommendations for mild pediatric HS cases and inadequate risk assessment are significant concerns.
• Further research is needed to establish evidence-based guidelines for hereditary spherocytosis management.